ライフサイエンスコーパス: complete remission

1 a with more than 90% of the patients showing complete remission.

2 ur DNA was done in 107 patients who achieved complete remission.

3 tial clinical utility for surveillance after complete remission.

4 ponse rate (ORR) was 92%, with 73% achieving complete remission.

5 risk factor were candidates for SCT in first complete remission.

6 ival in patients achieving either partial or complete remission.

7 se, 282 (54%) received a transplant in first complete remission.

8 of HSCT for older patients with AML in first complete remission.

9 confined within the fibrous capsule achieved complete remission.

10 hole-exome sequencing in granulocytes during complete remission.

11 ed in 32 patients; 29 of them (91%) achieved complete remission.

12 .40, P<0.0001) increased chances of entering complete remission.

13 respectfully predicted in favour and against complete remission.

14 le for patients undergoing auto-HCT in first complete remission.

15 I patients in complete remission/unconfirmed complete remission.

16 up to 88.2%, with 2 in 3 patients achieving complete remission.

17 BMT, 30% of patients were not in morphologic complete remission.

18 ood-risk group, 35 patients (44%) achieved a complete remission.

19 Eight patients attained complete remission.

20 s (4%) who received DA-EPOCH-R alone were in complete remission.

21 nts (56%) received transplantations in first complete remission.

22 n the primary intention-to-treat analysis of complete remission.

23 Two of the patients had durable complete remissions.

24 lts, and about 50% show partial, rather than complete, remission.

25 Initially, 36 of 51 patients achieved complete remission, 14 of 51 achieved partial remission,

26 Clofarabine significantly improved complete remission (22% vs 12%; hazard ratio [HR] = 0.47

27 quency of stable disease >/=6 months/partial/complete remission [22% (high scores) vs. 9% (low scores

28 hree hundred and twenty-eight (63%) achieved complete remission; 23 relapsed.

29 His cancer remains in complete remission 3 years later without additional trea

30 outcome in our patients was excellent: 90.2% complete remission, 3.92% partial remission, 1.96% stabl

31 Six participants regained complete remission; 311 (60%) were in complete remission

32 han those without expression (median time to complete remission, 4.0 months vs 5.0 months).

33 ho received their transplantations in second complete remission, 50% for patients in >/= third comple

34 Among the patients who had complete remission, a higher percentage in the inotuzuma

35 bination regimens that increase frequency of complete remissions, accelerate time to remission, and o

36 patients with relapsed NHL or CLL, 2 entered complete remission after 2 and 3 infusions of kappa.CART

37 patients with BE treated by RFA, 56% were in complete remission after 24 months.

38 renal-limited ANCA-associated vasculitis in complete remission after a cyclophosphamide-glucocortico

39 ts with metastatic melanoma can have durable complete remission after discontinuation of pembrolizuma

40 res of MALT lymphomas, can achieve long-term complete remission after frontline Helicobacter pylori (

41 T can be spared in patients with (metabolic) complete remission after immunochemotherapy must be addr

42 Those who achieved complete remission after induction therapy were assigned

43 Patients and Methods Patients with AML in complete remission after induction therapy were randomly

44 526 patients achieved complete remission after induction, of whom 463 were ran

45 Complete remission after nearly 20 years is reasonably w

46 For those unable to achieve complete remission after two lines of chemotherapy or th

47 Ninety-six percent achieved complete remission, almost all within 4 weeks, and a low

48 Long-term complete remission and "cure" of T2DM, however, occur in

49 in the clofarabine patients who did not gain complete remission and also following relapse.

50 Response rate (complete remission and complete remission with incomplet

51 III was also associated with a lower rate of complete remission and decreased survival.

52 ht into the association between pathological complete remission and long-term outcomes in HER2-positi

53 s achieved persistent antibody depletion and complete remission and never relapsed.

54 esent a therapeutic breakthrough, leading to complete remission and overcoming resistance to FLT3 inh

55 of adult patients with T-ALL do not achieve complete remission and relapse, our results call for cli

56 mission was lower in the Rtx group, rates of complete remission and the composite renal end point did

57 efficacy measure, including the duration of complete remission and the frequency or severity of rela

58 Best LTR responses consisted of 25 (71%) complete remissions and 10 (29%) partial remissions.

59 The overall remission rate was 73% with 55% complete remissions and 18% partial remissions.

60 Overall, we observed 9 of 19 complete remissions and 3 of 19 partial remissions.

61 enotype was associated with a higher rate of complete remissions and with a lower frequency of cirrho

62 ete remission, 50% for patients in >/= third complete remission, and 0% for patients not in remission

63 ET-NUP214-positive patients but one achieved complete remission, and 9 were allografted.

64 mpairment were intensified enough to achieve complete remission, and addition of BEV increased cell d

65 4%, and 72% in children with IIS resistance, complete remission, and partial remission, respectively;

66 ese drugs have markedly improved the rate of complete remission, and time to progression, progression

67 Relapses after complete remission are rare making this an acceptable pr

68 yeloid leukemia (AML) who are in morphologic complete remission are typically considered separately f

69 esponses in advanced cutaneous melanoma, but complete remissions are frustrated by the development of

70 Eleven of 12 complete remissions are ongoing.

71 inase inhibitor imatinib mesylate (Gleevec), complete remissions are rare and the majority of patient

72 esity-related comorbidities, and partial and complete remission at 1, 3, and 5 years of follow-up.

73 The primary end point was complete remission at 24 weeks.

74 Hematologic very good partial or complete remission at 6 months improved renal outcome in

75 FR and a 69% reduction in the probability of complete remission at any time, independent of histologi

76 hs of their diagnosis and had not achieved a complete remission at day 100.

77 Baseline factors predicting against complete remission at last contact included onset age>/=

78 gained complete remission; 311 (60%) were in complete remission at last contact.

79 investigational FLT3 inhibitors can achieve complete remissions but their utility has been hampered

80 adult acute lymphoblastic leukemia in first complete remission, but the optimal strategy remains con

81 All patients in complete remission by 6 months remained in remission at

82 presence of disease in cases deemed to be in complete remission by conventional pathologic analysis.

83 sive therapy patients, we compared chance of complete remission by logistic regression analysis and u

84 udies, CD38-bispecific PRIT resulted in 100% complete remissions by day 12 in MM and NHL xenograft mo

85 busulfan, and melphalan group had stringent complete remission compared with 22 of 174 patients (12.

86 ase confined by the fibrous capsule achieved complete remission, compared with complete remission in

87 karyotypes and led to lower remission rates (complete remission + complete remission with incomplete

88 ent groups (classical healing concept or the complete remission concept) to investigate differences i

89 ledge, of patients with DHL to achieve first complete remission, consolidative autoSCT was not associ

90 Patients in complete remission continued consolidation with dasatini

91 Overall, complete remission (CR [complete remission] + CRi [CR wi

92 one (91%) of 45 patients with aGVHD achieved complete remission (CR) after ECP.

93 patients achieved a molecular or hematologic complete remission (CR) after T-cell therapy, upon emerg

94 by quantitative polymerase chain reaction at complete remission (CR) and at 3-month time points, and

95 This manuscript evaluates complete remission (CR) and partial remission (PR) of pr

96 MRD) levels >/=10(-3) at day 78 (MRD-HR), no complete remission (CR) at day 33, t(4;11) translocation

97 y was to improve outcome for patients not in complete remission (CR) before transplant by adding (90)

98 sing RNA-Seq to compare the RR group and the complete remission (CR) group (a total of 42 adult AML p

99 he combination successfully led to a durable complete remission (CR) in a patient whose disease was r

100 Results Achievement of complete remission (CR) in the absence of MRD negativity

101 ients and 132 (97%) of 136 patients achieved complete remission (CR) in the ATRA-ATO and ATRA-CHT arm

102 All patients achieved complete remission (CR) in the bone marrow by flow cytom

103 Achieving BM MRD-negative complete remission (CR) is associated with superior prog

104 ffuse large B-cell lymphoma (DLBCL) in first complete remission (CR) is controversial and plays a lim

105 mes were observed in patients who achieved a complete remission (CR) on brentuximab vedotin, with est

106 The primary endpoint was complete remission (CR) or CR with partial haematologica

107 The primary end point was complete remission (CR) or CR with partial hematologic r

108 The primary end point was complete remission (CR) or CR with partial hematologic r

109 nt was offered to selected patients in first complete remission (CR) or unconfirmed CR.

110 ulting in a significantly higher hematologic complete remission (CR) rate and an equivalent major mol

111 A low score was associated with a higher complete remission (CR) rate and longer disease-free sur

112 ent-related mortality, and effective, with a complete remission (CR) rate of 34%.

113 jective response rate (ORR) was 100% and the complete remission (CR) rate was 62%.

114 The complete remission (CR) rate was 92% in the imatinib coh

115 With fewer induction deaths, the complete remission (CR) rate was higher in arm A than in

116 end points included objective response rate, complete remission (CR) rate, progression-free survival

117 Principal end points were safety and complete remission (CR) rate.

118 Complete remission (CR) rates as high as 90% have been r

119 despite achievement of progressively higher complete remission (CR) rates.

120 n 1 (TKD1, P = .06) were associated with low complete remission (CR) rates.

121 3 months, participants given FP who were in complete remission (CR) received 880 mcg FP daily, and p

122 Patients in complete remission (CR) received a single consolidation

123 ith acute myeloid leukemia (AML) who achieve complete remission (CR) relapse with conventional postre

124 a (NPM1mut-AML) patients have a high rate of complete remission (CR) to induction chemotherapy.

125 Complete remission (CR) was defined as Birmingham Vascul

126 al residual disease (MRD) and achievement of complete remission (CR) with incomplete platelet recover

127 Complete remission (CR) with persistence of mIDH2 and no

128 Patients in complete remission (CR) without evidence of minimal resi

129 Results Patients with MRD-negative complete remission (CR), MRD-negative PR, MRD-positive C

130 ous leukemia (AML) frequently relapses after complete remission (CR), necessitating improved detectio

131 We defined complete remission (CR), partial remission (PR), and rel

132 ith acute myeloid leukemia (AML) who achieve complete remission (CR), ultimately relapse.

133 les taken from patients who went on to enter complete remission (CR), whereas MDR(+) blasts were freq

134 ormed on 702 adults undergoing HSCT in first complete remission (CR).

135 stance (high vs low probability of achieving complete remission [CR]); (3) anticipated treatment-rela

136 end point was overall improvement rate (OIR: complete remission [CR], partial remission [PR], marrow

137 rapies, and the short-term remission status (complete remission [CR], partial remission [PR], no remi

138 who did not undergo transplantation in first complete remission (CR1) and to assess the contribution

139 Patients who were transplanted in first complete remission (CR1) had superior OS compared with t

140 ome in acute myeloid leukemia (AML) in first complete remission (CR1).

141 Overall, second complete remission (CR2) rate was 88%.

142 sess the contribution of allograft in second complete remission (CR2) with respect to major risk grou

143 mended monotherapy dose of 40 microg/kg, the complete remission + CRi rate was 28% (5 of 18 patients)

144 Overall, complete remission (CR [complete remission] + CRi [CR with incomplete recovery o

145 ients obtained remission, which included six complete remissions (CRs) and two partial remissions.

146 se rate was 44% for DLBCL, including 8 (17%) complete remissions (CRs) with a median duration of 16.6

147 Of 15 patients, eight achieved complete remissions (CRs), four achieved partial remissi

148 vemurafenib approached 100%, with 35% to 40% complete remissions (CRs).

149 Of 34 evaluable patients, ORR was 41% (8 complete remissions [CRs], 6 partial remissions [PRs]),

150 ipants concluded that the goal of therapy is complete remission, defined as both symptomatic and endo

151 The rate of complete remission did not associate with monogenic clas

152 venous cyclophosphamide group (25.6%) showed complete remission (difference, 20.3 percentage points [

153 Median first complete remission duration was 12.1 months (range, 2.1-

154 Older age and shorter first complete remission duration was associated with a shorte

155 hout treatment and 26 patients [28%] were in complete remission during adjuvant treatment).

156 Importantly, in mice with complete remission, echinomycin appeared to completely e

157 Methods Patients with DHL who achieved first complete remission following completion of front-line th

158 medications) in 11%, and "cure" (continuous complete remission for >/=5 years) was achieved in 3%.

159 rs developed confirmed clinical responses (1 complete remission >4 years, 2 partial response).

160 y-diagnosed epilepsy (onset age 0-15 years), complete remission, >/=5 years both seizure-free and med

161 on or as consolidation after attainment of a complete remission has become an established element in

162 ission (HbA1c <6.5% off medications) in 26%, complete remission (HbA1c <6% off medications) in 11%, a

163 After >/= 18 months in complete remission, imatinib was tapered and discontinue

164 e achieved complete remission, compared with complete remission in 13 (72%) of 18 patients with a tum

165 SM were observed in 40 patients (70%), with complete remission in 16 patients (28%).

166 sulfan, and melphalan who achieved stringent complete remission in accordance with the International

167 ood vessel FAK expression is associated with complete remission in human lymphoma.

168 al was strongly associated with pathological complete remission in patients given trastuzumab.

169 targeting CD19, which offer the prospect of complete remission in patients with chemorefractory or r

170 gager blinatumomab targeting CD19 can induce complete remission in relapsed or refractory B-cell prec

171 A higher proportion of patients achieved complete remission in the vosaroxin plus cytarabine grou

172 t inhibition of NPM-ALK induces long-lasting complete remissions in a large subset of heavily pretrea

173 nt anticancer agents that have produced many complete remissions in leukemia, but immunogenicity limi

174 ith metastatic urothelial cancers, including complete remissions in patients with chemotherapy refrac

175 ukemia (CLL) but as monotherapy produces few complete remissions in previously treated patients.

176 ategy decreasing relapse rates and enhancing complete remissions in this poor prognostic subgroup of

177 The primary end points were complete remission (including complete remission with in

178 Response rate (complete remission + incomplete remission) was the prima

179 der with AML that had relapsed after a first complete remission lasting less than 12 months, or had a

180 Consequently, IgA-positive patients achieved complete remission less frequently (adjusted hazard rati

181 Those achieving sustained partial or complete remission (n=287 [44%]) were randomly assigned

182 retargeted (90)Y-DOTA-biotin, including 100% complete remissions (no detectable tumor in treated mice

183 ent antileukemic activity was observed, with complete remission obtained in 73% (11/15) of patients r

184 Complete remission occurred in 6 of 14 patients with dif

185 Complete remissions occurred in 20% of the patients, inc

186 ne patients (52.6%) in the surgery group had complete remission of diabetes and 5 (6.4%) had partial

187 Complete remission of diabetes was maintained in 50.7%,

188 bcutaneous doses 2 weeks apart, resulting in complete remission of disease off therapy.

189 reatment induces granulocytic maturation and complete remission of leukemia.

190 Outcomes included sustained complete remission of neoplasia or intestinal metaplasia

191 A higher rate of complete remission of T2DM was observed in patients with

192 Partial and complete remission of T2DM were 50% and 17%, respectivel

193 During complete remission of the AML, in the presence of normal

194 patient we achieved a temporary (13 months) complete remission of the lymphoma by oral treatment wit

195 ); serious or nonserious events; partial and complete remission of the nephrotic syndrome; and a comp

196 specific for EBV antigens have also produced complete remissions of EBV-positive nasopharyngeal carci

197 DC/CoAT induced durable and complete remissions of large subcutaneous tumors without

198 Complete remission off anti-seizure medications is possi

199 using the same dosage regimen, again induced complete remission off therapy, which remained at9 month

200 Among 12 patients who achieved complete remission on earlier trials (ALL 97/99 and UKAL

201 f eosinophilic esophagitis (EoE) who achieve complete remission on PPI therapy.

202 responses at 12 weeks yielded two continuous complete remissions, one partial response (PR) using REC

203 6 years of age at diagnosis and had achieved complete remission or complete remission unconfirmed aft

204 mg/day, 80 mg/day, and 160 mg/day) achieved complete remission or complete remission with incomplete

205 Seven patients (10%) had complete remission or complete remission with incomplete

206 Patients in complete remission or partial remission received six rei

207 Complete remission or partial remission was achieved in

208 ciated with therapy intensity, likelihood of complete remission, or survival (high income: adjusted H

209 and for the 34 patients (19.3%) who attained complete remission, overall survival was 19.7 months.

210 h improved OS among patients achieving first complete remission (P = .14).

211 ume decreased significantly in patients with complete remission (P = 0.03).

212 , the next 5 years, and then >10 years after complete remission (P=0.06 for trend).

213 s the rate of hematologic normalization (HN; complete remission + partial remission + trilineage hema

214 nders and partial remission patients than in complete remission patients.

215 Once in complete remission, patients received 4 cycles of ATRA p

216 FCR improved complete remission, PFS and overall survival vs the comp

217 even upon transient achievement of clinical complete remission, pointing to a critical role of these

218 CI, 1.57 to 27.40; P=0.01), whereas initial complete remission protected from the event (HR, 6.63; 9

219 In patients who experienced complete remissions, PRs, or stable disease, the persist

220 The overall response rate was 72% (complete remission [R]/major/partial R: 0%/47%/25%) and

221 one marrow minimal residual disease-negative complete remission rate (64% vs 43%, P = .016).

222 There was no overall difference in complete remission rate (73% vs 75%; odds ratio, 1.07 [0

223 esponse rates (90% v 87%), achieved a higher complete remission rate (78% v 65%; P = .025).

224 After 6 cycles, the complete remission rate (CRR) was 64%, and 36% were MRD

225 pliceosome mutations associated with a lower complete remission rate (P = 0.03).

226 The complete remission rate /complete remission with incompl

227 UP98/NSD1 (82% of NUP98/NSD1 patients) had a complete remission rate of 27% vs 69% in FLT3/ITD withou

228 ts treated with rituximab and thiotepa had a complete remission rate of 49% (95% CI 38-60), compared

229 successful in 115, resulting in a long-term complete remission rate of 93.8%; 111 died of concomitan

230 The complete remission rate was 96% (52 of 54 in high-risk a

231 Complete remission rate was 96% and 65% of patients achi

232 The high complete remission rate with first-line combined fludara

233 were maximum-tolerated dosage (phase I) and complete remission rate within the first two cycles (pha

234 endpoint of the first randomisation was the complete remission rate, analysed by modified intention

235 h worse clinical outcomes, including a lower complete remission rate, more frequent reinduction, and

236 Complete remission rates (89%) did not differ but were a

237 vival (OS), relapse-free survival (RFS), and complete remission rates (CR) were not influenced by the

238 Complete remission rates after induction tended to be lo

239 toxic exposure was associated with decreased complete remission rates and inferior survival (3-year a

240 IL2DT was associated with improved complete remission rates at day 28 (53% vs 21%; P = .02)

241 In spite of high complete remission rates in Acute Myeloid Leukemia (AML)

242 uced an almost 100% response rate, including complete remission rates of 35% to 42%, without myelotox

243 n strategies continue to focus on increasing complete remission rates that allow more transplant-elig

244 d 83% after 1, 3, and 5 years, respectively; complete remission rates were 5%, 24%, and 38% at 1, 3,

245 Complete remission rates with or without adjuvant treatm

246 EGFL7 mRNA expression associates with lower complete remission rates, and shorter event-free and ove

247 sion, those with higher expression had lower complete remission rates, higher primary refractory rate

248 Patients in complete remission received maintenance with ponatinib 4

249 psed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon.

250 All patients who did not achieve complete remission remained PET-positive (P = 0.02).

251 achieved a response, with 19 (8%) achieving complete remission, ten (4%) complete remission with inc

252 r in samples from patients with pathological complete remission than in samples from patients with di

253 ry, and the patient's MM entered a stringent complete remission that lasted for 17 weeks before relap

254 L with all-trans retinoic acid and achieving complete remission, the levels of PGD2, NKp30, ILC2s, IL

255 Complete remission (tumor-free fraction, 100%) was found

256 nosis and had achieved complete remission or complete remission unconfirmed after first-line rituxima

257 phylaxis or radiotherapy to ECFI patients in complete remission/unconfirmed complete remission.

258 udy start 67% of the animals were in stable, complete remission vs. 0% for the Abraxane(R) only group

259 dy start, 42% of the animals were in stable, complete remission vs. 0% for the paclitaxel only group

260 The rate of complete remission was 88% (319/363); overall survival (

261 However, complete remission was achieved first at activity levels

262 Complete remission was achieved in 27 patients (90%), in

263 Complete remission was achieved in 40% (6/15 of evaluabl

264 g standard-dose cytarabine and daunorubicin, complete remission was achieved in 65% of patients.

265 Complete remission was achieved in all 77 patients in th

266 Complete remission was attained in 282 (87%) of 326 pati

267 Complete remission was defined as glycated hemoglobin (A

268 -C), and all-trans retinoic acid (ATRA), and complete remission was documented 5 weeks later.

269 The rate of complete remission was higher with inotuzumab ozogamicin

270 tly slower in the aFP + anti-PD-1 groups and complete remission was observed for tumors on both aFP-t

271 Complete remission was observed in one patient with TC,

272 groups (aFP and aFP + anti-PD-1 groups) and complete remission was observed in the aFP-treated group

273 The rate of complete remission was significantly higher in the inotu

274 t t(8;21) patients who received allo-HSCT in complete remission were enrolled.

275 Factors predicting for complete remission were uncomplicated epilepsy presentat

276 All 25 complete remissions were preceded by complete anti-PLA2R

277 than 12 months, or had achieved no previous complete remission, were randomly assigned (1:1) to rece

278 The patient had complete remission with antibiotic and anti-inflammatory

279 ions, and 86% of evaluable patients achieved complete remission with DA-TEDDi-R.

280 tients with relapsed/refractory ALL achieved complete remission with full (CR) or partial (CRh) hemat

281 the chemotherapy group, both with respect to complete remission with full hematologic recovery (34% v

282 y (34% vs. 16%, P<0.001) and with respect to complete remission with full, partial, or incomplete hem

283 io for an event of relapse after achieving a complete remission with full, partial, or incomplete hem

284 Response rate (complete remission and complete remission with incomplete blood count recovery)

285 with incomplete platelet recovery, 46 (18%) complete remission with incomplete haematological recove

286 nd points were complete remission (including complete remission with incomplete hematologic recovery)

287 The complete remission rate /complete remission with incomplete platelet recovery rat

288 (8%) achieving complete remission, ten (4%) complete remission with incomplete platelet recovery, 46

289 ven patients (10%) had complete remission or complete remission with incomplete platelet recovery: tw

290 d 160 mg/day) achieved complete remission or complete remission with incomplete recovery of platelets

291 lower remission rates (complete remission + complete remission with incomplete recovery), inferior e

292 acute myeloid leukemia (AML) do not achieve complete remission with intensive induction therapy and

293 efined as those patients in first partial or complete remission with no more than two lines of chemot

294 ncrease the proportion of patients achieving complete remission with or without complete peripheral c

295 Complete remission with undetectable anti-VWF occurred o

296 and P = .047 between groups for partial and complete remission), with no remission in the LWLI group

297 ed that nearly all patients (98.4%) achieved complete remission within the first three steps.

298 osage, 27 (39%; 95% CI, 27% to 51%) achieved complete remission within the first two cycles, 14 (52%)

299 Complete remission without minimal residual disease seem

300 ollow-up were 89% (56 patients [61%] were in complete remission without treatment and 26 patients [28